Comparative effects of Salvizan gel (containing Salvia officinalis extract) and triamcinolone acetonide gel on the duration and symptoms of oral lichenoid reactions
DOI:
https://doi.org/10.5195/d3000.2022.157Λέξεις-κλειδιά:
Lichenoid reaction, Gel, Scarlet sage, TriamcinoloneΠερίληψη
Objectives: Lichenoid reactions are disorders with similar clinical presentations. The current study was conducted to compare the improvement indices in the patients’ symptoms by Salvizan and triamcinolone gels. Therefore, regardless of the cause, eliminating the pain and symptoms is one of the objectives of the treatment.
Methods: This study was designed as a randomized double-blind clinical trial. Diagnosis of patients was performed by clinical examinations and confirmed by histological evaluation. One group of patients was administered Salvizan and another group was administered triamcinolone. After washing their mouth, the patients administered the gel (1 cm) on the inflammatory mucosa three times a day for two weeks. The amelioration rate of the lesions in each visit was measured from according to Visual Analog Scale (VAS) on a scale of 0-10.
Results: The results of repeated measures ANCOVA showed a significant difference between groups in terms of the pain intensity before treatment (p<0.001). Moreover, there was a significant difference between different times with regard to pain intensity (p=0.004). To evaluate the clinical indices in the study groups, Mann-Whitney test was used and the results showed no significant difference for the extent of lesions before treatment (p=0.874), after one week (p=0.503) and after two weeks (p=0.669).
Conclusions: Salvizan could better reduce pain intensity than triamcinolone, but clinically no significant difference was reported between the drugs in terms of the extent of lesion.
Αναφορές
Marx RE, Stern D. Oral and maxillofacial pathology. Chicago: Quintessence 2003;789-91.
Damm DD, Bouquot JE, Neville BW, Allen C. Oral and maxillofacial pathology. Chap. 2002;1:66.
Austyn JM, Wood K. Principles of cellular and molecular immunology Revista do Instituto de Medicina Tropical de São Paulo 1994;36(3):224-.
Edwards PC, Kelsch R. Oral lichen planus:clinical presentation and management. J Can Dent Assoc 2002;68(8):494-9
Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol 1991;25(4):593-619.
Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, Axéll T, Bruce AJ, Carpenter W, Eisenberg E, Epstein JB. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:25-e.
McCreary CE, McCartan BE. Clinical management of oral lichen planus. Br J Oral Maxillofac Surg 1999;37(5):338-43.
Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral Dis 1999;5(3):196-205.
Martin MD, Sherman J, Van Der Ven P, Burgess J. A controlled trial of a dissolving oral patch containing glycyrrhiza (licorice) herbal extract for the treatment of aphthous ulcers. Gen Dent 2008;56:206-210.
Willershausen B, Gruber I, Hamm G. The influence of herbal ingredients on the plaque index and bleeding tendency of the gingiva. J Clin. Dent 1991;2(3):75-8.
Cherevatyi VS, Vashchenko TN, Shishkov GZ. Comparative evaluation of the antibacterial action of different extracts from Salvia officinalis. Rastitel'nye Resursy 1980;16(1):137-9.
Taheri E, Ghorbani S, Safi M, Sani NS, Amoodizaj FF, Heidari M, Chavoshi R, Hajazimian S, Isazadeh A, Heidari M. Inhibition of colorectal cancer cell line CaCo-2 by essential oil of Eucalyptus camaldulensis through induction of apoptosis. Acta Med Iran. 2020;58(6):260-265.
Isazadeh A, Hajazimian S, Mashayekhi M, Shadman B, Bedoustani AB, Safaei S, Chavoshi R, Shanehbandi D, Baradaran B, Nahaei M. Anti-cancer Effects of Probiotic Lactobacillus acidophilus for Colorectal Cancer Cell Line Caco-2 through Apoptosis Induction. Pharm Sci. 2021;27(2):368-373.
Jadid MF, Shademan B, Chavoshi R, Seyyedsani N, Aghaei E, Taheri E, Goleij P, Hajazimian S, Karamad V, Behroozi J, Sabet MN. Enhanced anticancer potency of hydroxytyrosol and curcumin by PLGA‐PAA nano‐encapsulation on PANC‐1 pancreatic cancer cell line. Environ Toxicol. 2021;36(6):1043-1051.
Willershausen B, Gruber I, Hamm G. The influence of herbal ingredients on the plaque index and bleeding tendency of the gingiva. J Clin Dent 1991;2(3):75-8.
Cherevatyî VS, Vashchenko TN, Shishkov GZ. Comparative evaluation of the antibacterial action of different extracts from Salvia officinalis. Rastitel'nye Resursy 1980;16(1):137-9.
Buajeeb W, Kraivaphan P, Pobrurksa C. Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus. Oral Surg Med Oral Patho Oral Radiol Endod 1997;83(1):21-5.
Kamath VV, Setlur K, Yerlagudda K. Oral lichenoid lesions-a review and update. Indian J Dermatol 2015;60(1):102.
Firouzi Amoodizaj F, Baghaeifar S, Taheri E, Farhoudi Sefidan Jadid M, Safi M, Seyyed Sani N, Hajazimian S, Isazadeh A, Shanehbandi D. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma. J Biochem Mol Toxicol. 2020;34(6):e22486.
Mahdavi S, Kheyrollahi M, Sheikhloei H, Isazadeh A. Antibacterial and Antioxidant Activities of Essential Oil on Food Borne Bacteria. Open Microbiol J. 2019;13(1):81-85.
Mahdavi S, Haj Azimian S, Isa Zadeh AR, Babash Pour M, Shishehgar R. Study of the antioxidant and antimicrobial effects of the ethanolic extract of Eucalyptus camaldulensis Dehnh against infectious bacteria isolated from clinical and animal sources. J Comparative Pathobiol. 2017;13(4):2063-70.
Sookto T, Srithavaj T, Thaweboon S, Thaweboon B, Shrestha B. In vitro effects of Salvia officinalis L. essential oil on Candida albicans. Asian Pac J Trop Biomed 2013;3(5):376-80.
Azizi A, Lawaf S. The comparison of efficacy of adcortyl ointment and topical tacrolimus in treatment of erosive oral lichen planus. J Dent Res Dent Clin Dent Prospects 2007;1(3):99-102.
Bendas ER, Abdullah H, El-Komy MH, Kassem MA. Hydroxychloroquine niosomes: a new trend in topical management of oral lichen planus. Int J Pharm 2013;458(2):287-95.
Λήψεις
Δημοσιευμένα
Τεύχος
Ενότητα
Άδεια
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
Revised 7/16/2018. Revision Description: Removed outdated link.